Search

Your search keyword '"Patel, Kanan"' showing total 16 results
Start Over Author "Patel, Kanan" Publisher wiley
16 results on '"Patel, Kanan"'

4. Validation of automated fluorescent‐based technology for measuring total nucleated cell viability of hematopoietic progenitor cell products

Author

Patel, Kanan A., primary, Patel, Nita, additional, Kim, Grace H., additional, Chape, Laura S., additional, Agbon, Kristianne Gail D., additional, Angulo Fuentes, Minnie P., additional, Barbosa, Francis‐Marie L., additional, Castellano, Ryan T., additional, Gonzalez, Gloria N., additional, Mathew, Sheeba, additional, Mantile‐Selvaggi, Giuditta, additional, and Reich‐Slotky, Ronit, additional

Published
2022
Full Text
View/download PDF

9. Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial

Author

Lam, Phillip H., primary, Dooley, Daniel J., additional, Fonarow, Gregg C., additional, Butler, Javed, additional, Bhatt, Deepak L., additional, Filippatos, Gerasimos S., additional, Deedwania, Prakash, additional, Forman, Daniel E., additional, White, Michel, additional, Fletcher, Ross D., additional, Arundel, Cherinne, additional, Blackman, Marc R., additional, Adamopoulos, Chris, additional, Kanonidis, Ioannis E., additional, Aban, Inmaculada B., additional, Patel, Kanan, additional, Aronow, Wilbert S., additional, Allman, Richard M., additional, Anker, Stefan D., additional, Pitt, Bertram, additional, and Ahmed, Ali, additional

Published
2017
Full Text
View/download PDF

12. Higher risk for incident heart failure and cardiovascular mortality among community‐dwelling octogenarians without pneumococcal vaccination

Author

Ahmed, Momanna B., primary, Patel, Kanan, additional, Fonarow, Gregg C., additional, Morgan, Charity J., additional, Butler, Javed, additional, Bittner, Vera, additional, Kulczycki, Andrzej, additional, Kheirbek, Raya E., additional, Aronow, Wilbert S., additional, Fletcher, Ross D., additional, Brown, Cynthia J., additional, and Ahmed, Ali, additional

Published
2015
Full Text
View/download PDF

13. Effect of oral digoxin in high‐risk heart failure patients: a pre‐specified subgroup analysis of the DIG trial

Author

Gheorghiade, Mihai, primary, Patel, Kanan, additional, Filippatos, Gerasimos, additional, Anker, Stefan D., additional, van Veldhuisen, Dirk J., additional, Cleland, John G.F., additional, Metra, Marco, additional, Aban, Inmaculada B., additional, Greene, Stephen J., additional, Adams, Kirkwood F., additional, McMurray, John J.V., additional, and Ahmed, Ali, additional

Published
2013
Full Text
View/download PDF

15. Impairment of activities of daily living and incident heart failure in community-dwelling older adults

Author

Bowling, C. Barrett, primary, Fonarow, Gregg C., additional, Patel, Kanan, additional, Zhang, Yan, additional, Feller, Margaret A., additional, Sui, Xuemei, additional, Blair, Steven N., additional, Alagiakrishnan, Kannayiram, additional, Aban, Inmaculada B., additional, Love, Thomas E., additional, Allman, Richard M., additional, and Ahmed, Ali, additional

Published
2012
Full Text
View/download PDF

16. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.

Author

Lam PH, Dooley DJ, Fonarow GC, Butler J, Bhatt DL, Filippatos GS, Deedwania P, Forman DE, White M, Fletcher RD, Arundel C, Blackman MR, Adamopoulos C, Kanonidis IE, Aban IB, Patel K, Aronow WS, Allman RM, Anker SD, Pitt B, and Ahmed A

Subjects
Angiotensin-Converting Enzyme Inhibitors administration & dosage, Canada epidemiology, Cause of Death trends, Dose-Response Relationship, Drug, Double-Blind Method, Europe epidemiology, Follow-Up Studies, Heart Failure mortality, Heart Failure physiopathology, Humans, Stroke Volume physiology, Survival Rate trends, Treatment Outcome, United States epidemiology, Enalapril administration & dosage, Heart Failure drug therapy, Stroke Volume drug effects
Abstract

Aims: To examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial., Methods and Results: Two thousand five hundred and sixty-nine patients with HFrEF (ejection fraction ≤35%) were randomized to below-target (5-10 mg/day) dose placebo (n = 1284) or enalapril (n = 1285). One month post-randomization, blind up-titration to target (20 mg/day) dose was attempted for both study drugs in 2458 patients. Among the 1444 patients who achieved dose up-titration (placebo, n = 748; enalapril, n = 696; mean dose for both groups, 20.0 mg/day), target dose enalapril (vs. target dose placebo) was associated with a 9% absolute lower risk of the combined endpoint of heart failure hospitalization or all-cause mortality [adjusted hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.60-0.81; P < 0.001] during 4 years of follow-up. Among the 1014 patients who could not achieve target dose (placebo, n = 486; enalapril, n = 528; mean dose for both groups, 8.8 mg/day), below-target dose enalapril (vs. below-target dose placebo) was associated with a 12% absolute lower risk of the combined endpoint of heart failure hospitalization or all-cause mortality (adjusted HR 0.68; 95% CI 0.57-0.81; P < 0.001). Among the 1224 patients receiving enalapril, target (vs. below-target) dose had no association with the combined endpoint of heart failure hospitalization or all-cause mortality (adjusted HR 1.04; 95% CI 0.87-1.23; P = 0.695)., Conclusion: In patients with HFrEF, the clinical benefits of ACE inhibitors appear to be similar at both below-target and target doses., (© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results